NCT04880785 - Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

June 12, 2023

Study Completion Date

April 9, 2024

Conditions

HIV Infections

Interventions

DRUG

Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]

change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD

Trial Locations (17)

H. Álvaro Cunqueiro, Vigo

CHUAC, A Coruña

H. de Elche, Alicante

H. General de Alicante, Alicante

H. Bellvitge, Barcelona

H. Clinic, Barcelona

H. del Mar, Barcelona

H. de Donosti, Donostia / San Sebastian

H. Fundación Jimenez Díaz, Madrid

H. Infanta Leonor, Madrid

H. La Princesa, Madrid

H. Príncipe de Asturias, Madrid

H. Severo Ochoa, Madrid

Hospital 12 de Octubre, Madrid

Hospital General Univ. Gregorio Marañón, Madrid

Hospital Univ. La Paz, Madrid

H. Virgen de la Victoria, Málaga